BioCentury
ARTICLE | Clinical News

BTA585: Phase IIa started

April 18, 2016 7:00 AM UTC

Aviragen (formerly Biota Pharmaceuticals Inc.) began a double-blind, placebo-controlled, U.K. Phase IIa trial to evaluate 100 mg oral BTA585 twice daily for 7 days in about 60 healthy adult volunteer...